^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | SHR-A2102 (Topoisomerase I inhibitor, Nectin-4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Title:
Heavy! Hengrui Medicine’s Nectin-4 ADC innovative drug SHR-A2102 has received fast track designation from the US FDA
Published date:
04/19/2024
Excerpt:
Recently, SHR-A2102 for injection, a nectin-4 antibody-drug conjugate (ADC) independently developed by Hengrui Medicine, was granted fast track designation (FTD) by the U.S. Food and Drug Administration (FDA). ), for the treatment of advanced urothelial cancer.
